BDKRB2 and hereditary angioedema: Using icatibant, a B2R blocker that efficiently reduce swelling episodes in patients with type-1 and acquired hereditary angioedema patients [96,97], this pharmacological intervention reduced viral load in brain tissues of mice challenged with an extremely high dose of virus (40 LD50).